Form 4: 4D Molecular Therapeutics Director Nancy Miller-Rich Reports Stock Option Grant

Director Nancy Miller-Rich of 4D Molecular Therapeutics reports the acquisition of stock options as part of the company's non-employee director compensation program.

Summary

• Nancy Miller-Rich, a director of 4D Molecular Therapeutics, filed a Form 4 with the SEC.
• The report details the grant of a stock option to purchase 22,500 shares of common stock at an exercise price of $25.15 on May 21, 2024.
• The stock option was automatically granted under the company's non-employee director compensation program.
• The options vest in equal monthly installments starting May 21, 2025, and will be fully vested by May 21, 2027, contingent upon continued service.
• The options will fully vest upon a Change in Control event as defined in the 2020 Incentive Award Plan.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard compensation practices and aligns director interests with shareholders.

Positives

• The stock option grant aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.
• The Change in Control provision provides additional incentive for strategic transactions that benefit shareholders.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common form of compensation for directors in publicly traded companies, particularly in the biotechnology sector, to align their interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a standard practice in the biotech industry.
• Companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals also utilize stock options as part of their director compensation packages.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term performance.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially leading to decisions that increase shareholder value.
• The vesting schedule incentivizes the director to remain engaged and contribute to the company's success over the long term.

Key Dates